Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Amneal Pharmaceuticals Second Quarter twenty twenty six Earnings Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony DeMeo. Good morning, and thank you for joining Amneal Pharmaceuticals' second quarter twenty twenty six earnings call. Today, we issued a press release reporting Q2 results. The earnings press release and presentation are available on the IR page of amneal.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions are forward looking statements that are based solely on information that is now available to us. Please see the sections entitled cautionary statements on forward looking statements in our press release and presentation for factors that may impact future performance. We also discuss non GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation. On the call today are Sharag and Shintu Patel, co founders and co CEOs, Casos Conideres, CFO Joe Renda, for Specialty and Jason Daley, Chief Legal Officer. I will now hand the call over to Sharag. Thank you. Good morning, everyone. Amneal is in the midst of the most transformative period in our company's history. We are growing as one of the America's leading affordable medicines businesses with an increasingly diversified and high impact medicines portfolio, including specialty brands, biosimilars, GLP-1s, and complex generics across dosage forms such as transdermals and injectables. As we execute our strategy, we are building a larger, more impactful Amneal. That continued momentum is reflected in our second quarter results, where the company delivered revenue of $796,000,000 adj...